

## PDF hosted at the Radboud Repository of the Radboud University Nijmegen

The following full text is a publisher's version.

For additional information about this publication click this link.

<http://hdl.handle.net/2066/109744>

Please be advised that this information was generated on 2017-12-06 and may be subject to change.

# The RNA-Binding Protein Human Antigen R Controls Global Changes in Gene Expression during Schwann Cell Development

Marta Iruarrizaga-Lejarreta,<sup>1</sup> Marta Varela-Rey,<sup>1</sup> Juan José Lozano,<sup>2</sup> David Fernández-Ramos,<sup>1</sup> Naiara Rodríguez-Ezpeleta,<sup>1</sup> Nieves Embade,<sup>1</sup> Shelly C. Lu,<sup>3</sup> Peter M. van der Kraan,<sup>4</sup> Esmeralda N. Blaney Davidson,<sup>4</sup> Myriam Gorospe,<sup>5</sup> Rhona Mirsky,<sup>6</sup> Kristján R. Jessen,<sup>6</sup> Ana María Aransay,<sup>1</sup> José M. Mato,<sup>1</sup> María L. Martínez-Chantar,<sup>1\*</sup> and Ashwin Woodhoo<sup>1\*</sup>

<sup>1</sup>CIC bioGUNE, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, 48160 Derio, Bizkaia, Spain, <sup>2</sup>Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas, Hospital Clinic Centre Esther Koplovitz, 08036 Barcelona, Spain, <sup>3</sup>Division of Gastrointestinal and Liver Diseases, University of Southern California Research Center for Liver Diseases, Keck School of Medicine, University of Southern California, Los Angeles, California 90033, <sup>4</sup>Experimental Rheumatology and Advanced Therapeutics, Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen Centre for Molecular Life Sciences, Medical Centre Nijmegen, 6525 GA Nijmegen, The Netherlands, <sup>5</sup>Laboratory of Cellular and Immunology, National Institute on Aging–Intramural Research Program, National Institutes of Health, Baltimore, Maryland 21224, and <sup>6</sup>Department of Cell and Developmental Biology, University College London, London WC1E 6BT, United Kingdom

An important prerequisite to myelination in peripheral nerves is the establishment of one-to-one relationships between axons and Schwann cells. This patterning event depends on immature Schwann cell proliferation, apoptosis, and morphogenesis, which are governed by coordinated changes in gene expression. Here, we found that the RNA-binding protein human antigen R (HuR) was highly expressed in immature Schwann cells, where genome-wide identification of its target mRNAs *in vivo* in mouse sciatic nerves using ribonomics showed an enrichment of functionally related genes regulating these processes. HuR coordinately regulated expression of several genes to promote proliferation, apoptosis, and morphogenesis in rat Schwann cells, in response to NRG1, TGF $\beta$ , and laminins, three major signals implicated in this patterning event. Strikingly, HuR also binds to several mRNAs encoding myelination-related proteins but, contrary to its typical function, negatively regulated their expression, likely to prevent ectopic myelination during development. These functions of HuR correlated with its abundance and subcellular localization, which were regulated by different signals in Schwann cells.

## Introduction

The myelinating Schwann cells in the peripheral nervous system (PNS) are derived from the neural crest via two transitional stages. First, neural crest cells generate Schwann cell precursors, which then give rise to immature Schwann cells that surround

large bundles of axons. Schwann cells then initiate radial sorting of axons by selectively segregating large-diameter axons and establishing one-to-one relationships with them. This prerequisite for myelination requires the matching of Schwann cell number to axons by proliferation and apoptosis, and cytoskeletal-mediated Schwann cell morphogenesis, processes controlled by three major signals: Neuregulin-1 (NRG1), transforming growth factor- $\beta$  (TGF $\beta$ ), and laminins (Jessen and Mirsky, 2005; Woodhoo and Sommer, 2008).

Global changes in gene expression accompany the profound phenotypic changes associated with Schwann cell development. Thus, genes associated with proliferation and apoptosis, which reach a peak in immature Schwann cells, are highly expressed at this stage. With subsequent development, as the cells exit the cell cycle and lose susceptibility to apoptosis, these genes are downregulated. Conversely, many myelination-related genes are significantly upregulated as immature Schwann cells differentiate into myelinating Schwann cells (Verheijen et al., 2003; D'Antonio et al., 2006a). Recent studies have started to unravel the transcriptional and posttranscriptional molecular mechanisms that control these coordinated changes in gene expression. Chromatin remodeling, via HDAC1 and HDAC2, and micro-

Received Nov. 23, 2011; revised Feb. 16, 2012; accepted Feb. 18, 2012.

Author contributions: M.I.-L., M.V.-R., and A.W. designed research; M.I.-L., M.V.-R., D.F.-R., and A.W. performed research; N.E., S.C.L., P.M.v.d.K., E.N.B.D., M.G., R.M., and K.R.J. contributed unpublished reagents/analytic tools; M.I.-L., M.V.-R., J.J.L., N.R.-E., A.M.A., J.M.M., M.L.M.-C., and A.W. analyzed data; A.W. wrote the paper.

This work was supported by grants from Instituto de Salud Carlos III (FIS, PS09/00094; Ministry of Health, Spain), Fundación Científica de la Asociación Española Contra el Cáncer (Cancer Infantil), and the Program Ramón y Cajal (Ministry of Science and Innovation, Spain) (A.W.), an International Joint Project grant from the Royal Society of Great Britain (K.R.J., A.W.), National Institutes of Health Grant AT-1576 (S.C.L., M.L.M.-C., J.M.M.), Plan Nacional from the Spanish Ministry of Science SAF2011-29851 (J.M.M.), Sanidad Gobierno Vasco 2012 (M.V.-R.), ETORTEK-2010 (M.L.M.-C.), Sanidad Gobierno Vasco 2008 (M.L.M.-C.), Educación Gobierno Vasco 2011 (M.L.M.-C.), and PI11/01588 (M.L.M.-C.). Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas is funded by the Instituto de Salud Carlos III. M.G. was supported by the National Institute on Aging–Intramural Research Program, National Institutes of Health.

The authors declare no competing financial interests.

\*A.W. and M.L.M.-C. contributed equally to this work.

Correspondence should be addressed to Ashwin Woodhoo, CIC bioGUNE, Technology Park of Bizkaia, 48160 Derio, Bizkaia, Spain. E-mail: awoodhoo@cicbiogune.es.

DOI:10.1523/JNEUROSCI.5868-11.2012

Copyright © 2012 the authors 0270-6474/12/324944-15\$15.00/0

RNAs have been shown to be essential for the control of Schwann cell numbers and induction of myelination (Chen et al., 2011; Dugas and Notterpek, 2011; Jacob et al., 2011).

Cytoplasmic control of mRNA turnover and translation rates, mediated by RNA-binding proteins (RBPs), is a major post-transcriptional mechanism that promotes rapid and appropriate spatiotemporal expression of encoded proteins in response to environmental and internal cues. Human antigen R (HuR), a member of the ELAV/Hu family of RBPs, is a ubiquitously expressed protein that is essential for embryonic development and plays an important role in a number of disorders, including cancer (Hinman and Lou, 2008; Vázquez-Chantada et al., 2009). HuR binds to the 5′- and 3′-untranslated region (UTR) of many mRNAs, generally promoting their stability and translation (Lebedeva et al., 2011; Mukherjee et al., 2011).

In this study, we found that HuR was highly expressed in immature Schwann cells, where genome-wide identification of its target mRNAs showed an enrichment of mRNAs encoding proteins with functions in regulating proliferation, apoptosis, and morphogenesis. Using *in vitro* silencing experiments, we found that HuR contributed to enhancing the expression of several genes induced by NRG1, TGFβ, and laminins, the three major signals involved in these processes. Chromatin immunoprecipitation analysis showed that p65 and SMAD2/3 bind to the *HuR* promoter *in vivo* to regulate its expression, likely to be triggered by NRG1 and TGFβ, respectively. Significantly, we found that HuR is a negative regulator of myelination since, although it is bound to several mRNAs encoding myelination-related proteins, it negatively regulated their expression. Finally, we found that HuR protein is greatly reduced *in vivo* as myelination progresses, a process likely to be controlled by Egr2-mediated ubiquitin proteolysis.

## Materials and Methods

**Animals.** Mice and rats of either sex were housed at the Animal Unit at CIC bioGUNE, and all procedures were approved by the institutional review committee on animal use. The Animal Unit of CIC bioGUNE is an Association for Assessment and Accreditation of Laboratory Animal Care-accredited facility.

**RNA immunoprecipitation.** Immunoprecipitation (IP) protocol of endogenous mRNA-transfected HuR complexes was performed as described by Keene et al. (2006). In brief, 500 μg of whole-cell lysate obtained from a pool of newborn (NB) or postnatal day 5 (P5) sciatic nerves from C57BL/6J mice of either sex were incubated with a suspension of protein A-Sepharose beads (Sigma-Aldrich), precoated with 15 μg of either IgG1 (BD Biosciences Pharmingen) or anti-HuR (Santa Cruz Biotechnology) antibodies. For RNA immunoprecipitation (RIP)-chip analysis, appropriate amounts of total RNA from four biological replicates of HuR and mock IPs, as well as two replicates of input mRNA from NB and P5 nerves were submitted to the Genomics Analysis Platform at CIC bioGUNE for analysis on MOUSE WG-6 V2 arrays (Illumina). For RIP-quantitative PCR (qPCR) analysis, bound mRNA was measured by real-time PCR analysis, normalized to *GAPDH* mRNA bound in a nonspecific manner to IgG1.

**Microarray analysis and gene ontology classification.** Data were extracted using BeadStudio data analysis software. Data were processed and normalized using Robust Spline normalization using Lumi bioconductor package (Du et al., 2008). The data for the probes with a detection *p* value ≥ 0.01 were excluded. Those detected with *p* value < 0.01 in at least one array were accepted as significant. For the detection of differentially expressed genes, a linear model was fitted to the data and empirical Bayes moderated *t* statistics were calculated using the limma package from Bioconductor. Adjustment of *p* values was done by the determination of false discovery rates using Benjamini–Hochberg procedure (Peart et al.,

2005; Smyth, 2005). Biological functional analysis was performed using the Ingenuity Pathway Analysis software (Ingenuity Systems). Fisher's exact test was performed with the *p* value threshold of 0.05 to identify molecular functional categories with statistical significance.

**Biotin pull-down assay.** Biotinylated transcripts were synthesized using cDNA that was prepared from sciatic nerves. Templates were prepared using forward primers that contained the T7 RNA polymerase promoter sequence (CCAAGCTTCTAATACGACTCACTATAGGAGA), as described previously (Li et al., 2002). Biotin pull-down assays were performed as described previously (Antic and Keene, 1997), and bound proteins were analyzed by Western blotting. In brief, the PCR-amplified fragments were purified and used as templates for *in vitro* synthesis of the corresponding biotinylated RNAs by MAXIScript kit (Applied Biosystems). Biotin pull-down assays were performed by incubating 40 μg of P5 sciatic nerve cell lysates with equimolar amounts of biotinylated transcripts for 1 h at room temperature. The complexes were isolated using paramagnetic streptavidin-conjugated Dynabeads (Invitrogen), and bound proteins in the pull-down material were analyzed by Western blotting using an antibody recognizing HuR. Primer sequences are available on request.

**RNA isolation and qPCR.** RNA was isolated with Trizol (Invitrogen), and its concentration and integrity were determined. qPCRs were performed using Bio-Rad iCycler thermocycler. Ct values were normalized to the housekeeping expression (*GAPDH*). Primer sequences are available on request.

**Protein isolation and Western blotting.** Isolation and Western blotting of total proteins from cells and nerves were done as described previously (Parkinson et al., 2008). Subcellular fractions were isolated using the Proteoextract Subcellular Proteome Extraction kit (Calbiochem), according to manufacturer's instructions. The purity of cytoplasmic and nuclear fractions was examined by Western blotting in each experiment using antibodies to Gapdh and Histone H3, respectively.

**Rat primary Schwann cell culture.** Sciatic nerves obtained from P3 Wistar rats of either sex were digested in 0.25% trypsin, 0.4% collagenase in DMEM, and cultured for 3 d in DMEM with 10% fetal bovine serum (FBS) containing AraC ( $10^{-3}$  M). After 3 d in culture, Schwann cells were immunopanned to remove remaining fibroblasts and expanded in DMEM/F12, 3% FBS, NRG1 (10 ng/ml), N2 supplement, and forskolin (4 μM). Only the first five passages were used. For proliferation experiments, cells were first cultured overnight in Minimal Medium (MM) (DMEM/F12, 5% FBS, and N2 supplement) before NRG1 (20 ng/ml) or TGFβ (2 ng/ml) stimulation at appropriate time points. For cell shape experiments, cells were cultured overnight in MM before replating onto poly-L-lysine (PDL)- or laminin-coated dishes. For apoptosis assays, freshly isolated Schwann cells from NB nerves were isolated, plated onto coverslips in Simple Medium (SM) [DMEM/F12 and BSA (0.3 mg/ml final)], and treated with TGFβ (2 ng/ml) for 48 h. Recombinant human TGFβ1 and NRG-1 (Heregulin-β1 isoform) were purchased from PeproTech and R&D Systems, respectively.

**Neuron–Schwann cell cocultures.** Myelinating neuron–Schwann cell cocultures were prepared by adding purified rat Schwann cells, infected with sh HuR lentivirus or adenovirus expressing HuR, to purified E15 rat DRG neurons. Myelination was induced with 50 mg/ml ascorbic acid, and myelin basic protein (MBP) antibodies were used to label myelin segments or RNA extracted (Parkinson et al., 2008).

**Viral infection.** For HuR knockdown, cells were treated with short-hairpin lentiviral particles against HuR (CCGGCCCCACAAATGTTAGACCAATTC TCGAGAATTGGTCTAACATTTGTGGGTTTTG) in the presence of hexadimethrine bromide (8 μg/ml). After 24 h transduction, the cells were selected using puromycin (1.25 μg/ml) and puromycin-resistant HuR-knockdown cell clones were grown, analyzed, and frozen for future use. For adenoviral infections, cells were cultured in MM, adenoviral particles were added (amount added determined by titration), and 24 h later the medium was changed. Adenoviral constructs used were as follows: GFP/Krox-20 (Ad-K20) and its matched GFP control (Ad-GFP) (a gift from J. Milbrandt, Department of Genetics, Washington University School of Medicine, St. Louis, MO) (Parkinson et al., 2004), SMAD7 (Ad-SMAD7) (Blaney Davidson et al., 2006), and HuR (Ad-HuR) (Xiao et al., 2007).

**Inhibitors.** Specific inhibitors in our culture experiments were obtained from Calbiochem and were used at the following concentrations: 10 μM

1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene (U0126) (ERK1/2 inhibitor), 10  $\mu$ M 4-[4-(4-fluorophenyl)-2-(4-methylsulfinylphenyl)-1*H*-imidazol-5-yl]pyridine (SB203580) (p38 inhibitor), 10  $\mu$ M 2-(4-morpholinyl)-8-phenyl-4*H*-1-benzopyran-4-one (LY294002) (PI3K inhibitor), 10  $\mu$ M *N*-(benzylloxycarbonyl)leucinylleucinylleucinal (MG132) (proteasome inhibitor), and 2  $\mu$ M 3-[(4-methylphenyl)sulfonyl]-(2*E*)-propenenitrile (BAY11-7082) (NF- $\kappa$ B inhibitor).

**Migration assay.** Migration using the “scratch assay” was performed as described previously (Liang et al., 2007). In brief, control and *HuR*-silenced cells were seeded onto PDL- or laminin-coated dishes and cultured overnight in MM. A scratch was performed using a p200 pipette tip, culture medium was changed, and pictures were taken at time 0, 6, 12, 18, and 24 h. The gap distance was measured at each time point, and data were expressed as percentage gap distance over time.

**cAMP myelination assay.** A cAMP analog, dibutyl-cAMP (Sigma-Aldrich) was added to cultures ( $10^{-3}$  M), and protein or mRNA was obtained 24 h later.


**Immunohistochemistry and immunocytochemistry.** For teased nerves, nerves were dissected out, immediately fixed in 4% PFA for 10 min, teased on microscope slides, and allowed to dry. The samples were incubated in 0.2% Triton in blocking solution (BS) (PBS containing 10% calf serum, 0.1% lysine, and 0.02% sodium azide) followed by overnight incubation at 4°C with the following primary antibodies: HuR (1:100) and TUJ1 (1:5000) followed by secondary antibodies conjugated with FITC or Cy3 (Cappel/Jackson ImmunoResearch Laboratories). Talin immunocytochemistry has been described previously (Nodari et al., 2007), and *in vitro* BrdU incorporation and TUNEL labeling described previously (Parkinson et al., 2001; D’Antonio et al., 2006b). Images were acquired with an AxioImager D1 fluorescent microscope (Zeiss).

**Chromatin immunoprecipitation.** Rat Schwann cells or whole nerves were cross-linked with 1% formaldehyde (v/v) at 25°C for 10 min. After sonication into 200–500 bp fragments using Bioruptor (Diagenode), chromatin was immunoprecipitated with 2  $\mu$ g of anti-p65 antibody (sc-372; Santa Cruz Biotechnology) or 5  $\mu$ g of anti-Smad2/3 antibody (3102; Cell Signaling Technology) using the Magna ChIP G kit (Millipore). The recovered DNA was subjected to PCR amplification. Chromatin that was immunoprecipitated with mouse IgG was used as a negative control. The abundance of target genome DNA was calculated as the percentage of input. Primer sequences are available on request.

**Antibodies.** Antibodies used were from the following: HuR and p65 (Santa Cruz Biotechnology), Gapdh (Abcam),  $\beta$ -actin and Talin (Sigma-Aldrich), p-ERK1/2, p-AKT, p-p38, Smad2/3 (Cell Signaling Technology), Egr2 and TuJ1 (Covance), MPZ (Astex), Periaxin (gift from P. Brophy, Centre for Neuroregeneration, University of Edinburgh, Edinburgh, UK), and MBP (Eurogentec). Fluorescent-conjugated secondary antibodies were from Jackson ImmunoResearch, and HRP-conjugated secondary antibodies were from Bio-Rad.

**Assessment of mRNA stability.** mRNA stability was determined by actinomycin D chase experiments, following a standard protocol described previously (Chang et al., 2010). Briefly, control and *HuR*-silenced cells were treated with db-cAMP for 24 h, which significantly increased expression of all mRNAs analyzed. Actinomycin D was added to a final concentration of 5  $\mu$ g/ml to block further transcription. At 0, 30, 60, 120, and 240 min after actinomycin D treatment, the cells were harvested and mRNA was quantified by qPCR. The mRNA decay was recorded as the percentage of mRNA remaining over time compared with the amount before the addition of actinomycin D.

**Statistical analysis.** All data are presented as arithmetic mean  $\pm$  SEM, unless otherwise stated. Statistical significance was estimated by Student’s *t* test.



**Figure 1.** HuR is differentially expressed in postnatal sciatic nerves. HuR expression is significantly reduced in P10 nerves, compared with NB and P5, as shown by qPCR (**a**), Western blotting of total protein extracts (**b**), and cytosolic and nuclear protein fractions (**c**). **d**, Immunohistochemistry showing HuR expression (red) in Schwann cells from P5 teased sciatic nerves (arrows). TuJ1 labels axons (green) and DAPI labels nuclei (blue). **b**, **c**, Gapdh/ $\beta$ -actin, loading control. **c**, Gapdh, Cytoplasmic marker; Histone H3, nuclear marker. Data are mean  $\pm$  SEM. \* $p < 0.01$ .

## Results

### HuR is highly expressed in immature Schwann cells

HuR is a ubiquitously expressed RBP that binds to and regulates expression of thousands of mRNAs (Lebedeva et al., 2011; Mukherjee et al., 2011), playing fundamental roles in proliferation, apoptosis, and differentiation in several systems and cell types (Hinman and Lou, 2008). To investigate whether HuR might have a role in Schwann cell development, we first examined its expression in rat sciatic nerves at different ages, as immature Schwann cells differentiate into myelinating Schwann cells (Woodhoo et al., 2009).

We found that *HuR* mRNA was highly expressed in NB nerves, which contain mostly immature Schwann cells, and P5, which contain a mixture of immature Schwann cell and actively myelinating Schwann cells. There was a small but significant downregulation in P10 nerves, which contain an enriched population of actively myelinating Schwann cells (Fig. 1*a*). This was confirmed by examining its expression in total protein extracts (Fig. 1*b*), although the decrease at protein level seen at P10 ( $\sim 70\%$  by densitometry analysis) was much more significant than at mRNA level ( $\sim 25\%$ ). A similar pattern of expression was found when nuclear and cytoplasmic protein subcellular fractions were analyzed (Fig. 1*c*). We confirmed that HuR was expressed in Schwann cells by immunohistochemistry in P5 teased nerves (Fig. 1*d*).


Our results indicate that HuR may have a functional role in early postnatal nerves since its abundance and cytoplasmic export both critically control expression of its target genes (Hinman and Lou, 2008).

### RIP-chip identifies several HuR target genes

To examine the biological significance of the high levels of HuR in NB and P5 Schwann cells, we analyzed the mRNAs bound to it on a genome-wide scale. For this, IP of ribonucleotide complexes (ribonucleoproteins) from cytoplasmic lysates of freshly isolated NB and P5 mouse sciatic nerves using an affinity-purified HuR antibody was performed, followed by purification and genome-wide microarray analysis of bound mRNAs (RIP-chip).

Two populations of mRNAs were detected in our analysis: an enriched population corresponding to the HuR-bound mRNAs and a nonenriched population representing background (control IP using mouse IgG) (Fig. 2*a*). To identify transcripts significantly associated with HuR, we used median log ratios of signal from RNA immunoprecipitation with HuR antibody versus the control IgG. HuR bound to 275 and 90 transcripts in NB and P5 nerves, respectively (Fig. 2*b,c*). Next, we examined the relation-





**Figure 2.** RIP-ChIP identifies several HuR targets *in vivo* in NB and P5 nerves. **a**, Heat map showing expression of the top transcripts most significantly bound to HuR compared with control IgG in NB nerves (top panel) and P5 nerves (bottom panel) in four different replicates (1–4). **b**, Heat map showing relative enrichment of top 50 mRNA targets of HuR, compared with control IgG (HuR IP/IgG IP, column 1) and input mRNA (HuR IP/Input, column 2). The color scale indicates the degree of enrichment (green–red ratio scale). **c**, Venn diagram showing the overlap of HuR-bound transcripts with a fold change  $\geq 1.5$  in lysates isolated from NB and P5 nerves. **d**, Enriched GO classification of the genes identified by the RIP-chip analyses in NB (blue histograms) and P5 nerves (red histograms).

ship between the levels of each HuR-bound transcript relative to its total cellular level. There was little correlation between the probability of HuR association and the transcriptome, with only  $\sim 25\%$  of total identified transcripts (HuR IP/IgG IP) found to be significantly enriched relative to total mRNA levels (HuR IP/input) in both cases (Fig. 2*b*). This shows that detection of transcripts in HuR IP fraction is not dependent on mRNA abundance and that there is no bias toward identification of highly abundant or transcribed genes, as shown in other systems (Hieronymus and Silver, 2003; Mukherjee et al., 2009).

Comparison of the identified transcripts in the NB and P5 nerves showed that approximately two-thirds of targets identified in P5 nerves were commonly present in NB nerves, whereas the large majority of transcripts identified in NB nerves were uniquely expressed (Fig. 2*c*). Using the data set of gene expression profiling in nerves of mice at different ages across the Schwann cell lineage (Verheijen et al., 2003), we found that  $\sim 25\%$  of these unique HuR targets in NB nerves were also significantly down-regulated in older nerves compared with NB nerves (50 of 215).

Since it was proposed that RBPs coordinate the expression

of transcripts encoding biologically related proteins (Keene, 2007), we performed Gene Ontology (GO) analyses of differentially regulated HuR mRNA targets in NB and P5 nerves. Functional classification into molecular and cellular function (MF) showed that most of the enriched genes fell into several categories related to proliferation, apoptosis, and morphogenesis (Fig. 2*d*).

To validate our results from the RIP-chip analysis, fresh IPs were performed, and expression of several genes related to proliferation, apoptosis, and morphogenesis was quantified by quantitative RT-PCR (RIP-qPCR). We found that, with some rare exceptions, there was a similar trend of enrichment of these HuR targets using both analyses (Table 1). Our RIP-chip analysis also revealed a significant enrichment of mRNAs encoding RBPs, including *HuR* itself, and *Thoc4* and *Hnrpl* among others, in line with other studies (Pullmann et al., 2007; Mansfield and Keene, 2009). This was confirmed by RIP-qPCR for selected genes (data not shown).

In summary, we find that HuR is bound to several mRNA targets in peripheral nerves *in vivo*, with decreasing binding af-

**Table 1. Validation of RIP-ChIP by RIP-qPCR**

Gene symbol	Gene name	NB		P5	
		Array	qPCR	Array	qPCR
Proliferation					
<i>Ccnd1</i>	Cyclin D1	5.54*	5.17*	1.32 <sup>n.s.</sup>	1.12 <sup>n.s.</sup>
<i>Ccnd2</i>	Cyclin D2	1.56*	2.31*	1.41 <sup>n.s.</sup>	1.19 <sup>n.s.</sup>
<i>Cdk2</i>	Cyclin-dependent kinase 2	2.55*	3.35*	1.29 <sup>n.s.</sup>	1.63 <sup>n.s.</sup>
<i>Serpine2</i>	Serine (or cysteine) peptidase inhibitor, clade E, member 2	1.78*	3.74*	−1.04 <sup>n.s.</sup>	1.61 <sup>n.s.</sup>
<i>Brd4</i>	Bromodomain containing 4	2.13*	3.73*	1.29 <sup>n.s.</sup>	1.12 <sup>n.s.</sup>
<i>ErbB2</i>	v-erb-b2 erythroblastic leukemia viral oncogene homolog 2	1.76*	5.17*	1.00 <sup>n.s.</sup>	1.09 <sup>n.s.</sup>
<i>Sox9</i>	SRY-box containing gene 9	3.38*	7.86*	1.70*	3.93*
<i>Shc1</i>	Src homology 2 domain-containing transforming protein C1	3.19*	6.52*	1.35 <sup>n.s.</sup>	1.09 <sup>n.s.</sup>
Cell morphology					
<i>Actb</i>	Actin, beta	59.1*	63.9*	26.3*	29.5*
<i>Ncam1</i>	Neural cell adhesion molecule 1	2.34*	4.65*	1.38 <sup>n.s.</sup>	1.06 <sup>n.s.</sup>
<i>Pfn1</i>	Profilin 1	3.98*	4.65*	5.56*	5.08*
<i>Ahnak</i>	AHNAK nucleoprotein (desmoyokin)	16.5*	12.7*	6.79*	6.89*
<i>Lamc1</i>	Laminin, gamma 1	2.32*	4.45*	1.06 <sup>n.s.</sup>	1.35 <sup>n.s.</sup>
<i>Calm3</i>	Calmodulin 3	6.62*	16.1*	2.66*	7.18*
<i>Igfbp5</i>	Insulin-like growth factor binding protein 5	4.29*	3.86*	1.69 <sup>n.s.</sup>	1.51 <sup>n.s.</sup>
<i>Marcks</i>	Myristoylated alanine-rich protein kinase C substrate	4.57*	9.83*	1.15 <sup>n.s.</sup>	1.60 <sup>n.s.</sup>
Apoptosis					
<i>Casp2</i>	Caspase 2	1.99*	5.11*	1.14 <sup>n.s.</sup>	1.87 <sup>n.s.</sup>
<i>Casp9</i>	Caspase 9	1.89*	3.68*	1.32 <sup>n.s.</sup>	1.68 <sup>n.s.</sup>
<i>AatK</i>	Apoptosis-associated tyrosine kinase	7.08*	12.6*	2.74*	5.20*
<i>Btg1</i>	B-cell translocation gene 1	2.82*	4.71*	1.13 <sup>n.s.</sup>	1.58 <sup>n.s.</sup>
<i>Map3k1</i>	Mitogen-activated protein kinase kinase kinase 1	1.7*	4.51*	1.12 <sup>n.s.</sup>	1.14 <sup>n.s.</sup>
<i>Cd44</i>	CD44 antigen	1.99*	6.24*	1.47 <sup>n.s.</sup>	5.01*
<i>Pdcd4</i>	Programmed cell death 4	2.57*	8.60*	2.11*	7.48*
<i>Vdac1</i>	Voltage-dependent anion channel 1	3.09*	6.14*	1.82 <sup>n.s.</sup>	3.63*

\* $p < 0.05$ ; n.s., not significant.

finity as development proceeds. The identified targets generally fall into categories that most closely characterize the immature Schwann cell stage (i.e., proliferation, apoptosis, and motility/morphogenesis), suggesting that HuR may have a functional role in regulating these processes.

### HuR mediates laminin-induced motility and morphogenesis


As mentioned above, before myelination, immature Schwann cells migrate extensively along axons and send processes within axon families to segregate and ensheath them. Laminin, one of the critical components of the basal lamina, plays a fundamental role in this process (Chernousov et al., 2008; Feltri et al., 2008).

To examine whether HuR mediated laminin-induced function in Schwann cells, we used a lentiviral vector to silence *HuR* (see Fig. 7*b* for effectiveness of *HuR* knockdown) and examined its effect on migration and morphogenesis. Using the cell scratch assay, we found that the migratory rate on laminin substrate was reduced in *HuR*-silenced cells compared with control cells (Fig. 3*a,b*), whereas no such effect was seen on PDL substrate, which promotes non-receptor-specific cell adhesion (data not shown). Similarly, on laminin substrate but not on PDL, *HuR*-silenced cells spread less and elaborated fewer lamellipodia than control cells (Fig. 3*c,d*). The length of axial lamellipodia on laminin substrate, which favors directional cell migration (Pankov et al., 2005), was reduced after *HuR* silencing (Fig. 3*e*), likely causing the defects in migratory rates seen above. In addition, we found that there was reduction in number of radial lamellipodia (Fig. 3*e*), which are important for the insertion of processes within axons during radial sorting (Nodari et al., 2007). These results show that HuR is an important mediator of laminin-induced function in Schwann cells.

Next, we investigated the mechanisms involved in these processes. First, by qPCR, we examined the expression of several of the validated HuR targets, associated with cell movement and morphogenesis in Schwann cells or in other systems, including *Pfn1* (Witke, 2004), *Marcks* (Larsson, 2006), *Igfbp5* (Yano et al., 1999), *Ncam1* (Yu et al., 2009), *Actin* (Chernousov et al., 2008), *Ahnak* (Salim et al., 2009), *Lamc1* (Chen and Strickland, 2003), and *Calm3* (Larsson, 2006). We found that culture on laminin substrate, compared with PDL, upregulated expression of several of these HuR targets (Fig. 3*f*). *Ahnak*, *Lamc1*, and *Calm3* were not regulated by laminin (data not shown). Using RIP-qPCR analyses, we also found that culture on laminin substrate significantly increased binding of HuR to only the regulated mRNAs (Fig. 3*g*) and that *HuR* silencing reduced their expression (Fig. 3*h*), likely explaining the defects in laminin function.

HuR-mediated stabilization and translational upregulation of target mRNAs are closely linked to its subcellular localization. It is predominantly (>90%) localized in the nucleus but, in response to different stimuli, is exported to the cytoplasm, a process modulated by several posttranslational modifications, which also affects its binding to target mRNAs (Doller et al., 2008). We found that laminin increased the nucleo-cytoplasmic translocation of HuR (Fig. 4*a*), an effect controlled by p38 phosphorylation (Fig. 4*b*), which has previously been shown to be important for laminin-induced cell shape changes (Fragoso et al., 2003; Berti et al., 2011). Treatment with the p38 inhibitor also significantly reduced Schwann cell migration on laminin substrate (Fig. 4*c*).

In summary, we show that laminin induces translocation of HuR from the nucleus to the cytoplasm and increases HuR-mediated stabilization of several mRNAs that regulate cell motility and morphogenesis in Schwann cells.



**Figure 3.** HuR mediates laminin-induced Schwann cell motility and morphogenesis. **a**, Cell scratch assay showing that migration on laminin-coated coverslips is significantly reduced in sh HuR-infected cells (\*\*) compared with sh control-infected cells (\*). **b**, Graphs showing the closure of the gap distance with time after culture on laminin-coated coverslips. **c**, Talin immunocytochemistry (red) showing morphological differences between sh HuR-infected and sh control-infected cells plated onto laminin. **d**, HuR-silenced cells have a smaller surface area and fewer lamellipodia on laminin substrate, but not on PDL. **e**, HuR-silenced cells have shorter axial lamellipodia and fewer radial lamellipodia than sh control-infected cells on laminin. **f**, qPCR showing expression of different transcripts after culture on laminin with time, expressed as fold change relative to cells replated onto PDL dishes. **g**, RIP-qPCR analysis shows significant enrichment of several motility/morphology-associated genes bound to HuR in cells plated onto laminin compared with cells plated onto PDL. **h**, HuR silencing leads to a significant reduction in expression of these genes. Data are mean  $\pm$  SEM. \* $p < 0.01$ .

### HuR mediates NRG1- and TGF $\beta$ -induced proliferation

Immature Schwann cell proliferate vigorously during late embryonic to perinatal stages (Stewart et al., 1993), a process thought to be critical for radial sorting and dependent on axonally derived mitogens, including NRG1 and TGF $\beta$  (Chernousov et al., 2008; Feltri et al., 2008; Woodhoo and Sommer, 2008).

Using established cell culture conditions that promote the mitogenic effect of NRG1 and TGF $\beta$  *in vitro* (Atanasoski et al.,

2004), we found that HuR silencing significantly reduced proliferation induced by these two growth factors (Fig. 5*a,b*). The percentage of BrdU<sup>+</sup> cells was significantly reduced from  $77.6 \pm 2.7\%$  in control cells to  $44.6 \pm 2.5\%$  in HuR-silenced cells after NRG1 treatment, and from  $30.1 \pm 1.5$  to  $17.8 \pm 1.1\%$  after TGF $\beta$  treatment ( $p < 0.01$ ). To investigate the mechanisms involved in this function of HuR, we first examined expression of HuR targets associated with proliferation, including *Cyclin D1* (Kim et al.,

2000), *Cyclin D2* (Jena et al., 2002), *Cdk2* (Tikoo et al., 2000), *Serpine 2* (Lino et al., 2007), *Shc1* (Ward et al., 1999), *Sox9* (Lincoln et al., 2007), *ErbB2* (Raphael et al., 2011), and *Brd4* (Houzelstein et al., 2002). We found that NRG1 and TGF $\beta$  treatment upregulated expression of several of these targets (Fig. 5c). RIP-qPCR analysis showed that NRG1 and TGF $\beta$  treatment significantly increased HuR binding to these mRNAs (Fig. 5d), the expression of which were significantly reduced by *HuR* silencing (Fig. 5e,f). We also found that NRG1 and TGF $\beta$  promoted the nucleocytoplasmic translocation of HuR (Fig. 6a). ERK1/2 and AKT phosphorylation controlled both NRG1-induced translocation of HuR and proliferation (Fig. 6b), whereas ERK1/2 and p38 phosphorylation controlled TGF $\beta$ -induced translocation of HuR and proliferation (Fig. 6c).

In summary, we show that HuR increases stability of genes in response to NRG1 and TGF $\beta$ , regulating their function on proliferation.

### HuR mediates TGF $\beta$ -induced apoptosis


Natural cell death, like proliferation, is a feature of immature Schwann cells, which is induced by TGF $\beta$  *in vivo* (D'Antonio et al., 2006b).

Using established cell culture conditions that promote the apoptotic effect of TGF $\beta$  in Schwann cells (Parkinson et al., 2001), we found that silencing of HuR significantly reduced apoptosis (Fig. 7a,b). The percentage of surviving cells increased from  $29.5 \pm 8.5\%$  in control cells to  $68.5 \pm 7.8\%$  in *HuR*-silenced cells, whereas the percentage of apoptotic TUNEL<sup>+</sup> cells decreased from  $49.2 \pm 6.7$  to  $13.5 \pm 2.3\%$  ( $p < 0.01$ ). Of note, these culture conditions are different from proliferation-inducing conditions (above). To investigate the mechanisms involved, we first examined expression of HuR targets associated with apoptosis, including *Aatf* (Tomomura et al., 2001), *Btg1* (Lee et al., 2003), *Caspase 2* (Kumar, 2009), *Caspase 9* (Riedl and Salvesen, 2007), *Vdac1* (Shoshan-Barmatz et al., 2010), *Pdcd4* (Lankat-Buttgereit and Göke, 2009), *Map3k1* (Parkinson et al., 2004), and *Cd44* (Rouschop et al., 2006). We found that TGF $\beta$  treatment upregulated expression of several of these HuR targets (Fig. 7c). RIP-qPCR analysis showed that TGF $\beta$  treatment significantly increased HuR binding to them (Fig. 7d), the expression of which was significantly reduced by *HuR* silencing (Fig. 7e). We also found that TGF $\beta$  induced the nucleocytoplasmic translocation of HuR (Fig. 7f), an effect controlled by p38 phosphorylation but not by ERK1/2 phosphorylation, which was not activated in these culture conditions (Fig. 7g). Treatment with specific inhibitors also had a similar effect on TGF $\beta$ -induced apoptosis (Fig. 7h).

Thus, we show that TGF $\beta$ -induced apoptosis is controlled by HuR-mediated stabilization of several apoptosis-related genes.

### HuR is a negative regulator of myelination

In our RIP-chip analysis, we found several myelination-related proteins (e.g., *Pmp22*, *Mpz*) encoded by mRNAs whose abundance was enriched in HuR IP samples, especially at the NB stage (Fig. 2b). We confirmed this observation for the *Pmp22* gene by RIP-qPCR (Fig.



**Figure 4.** Laminin induces nucleo-cytoplasmic translocation of HuR. **a**, Western blot showing nucleo-cytoplasmic translocation of HuR after replating of Schwann cells onto laminin. **b**, **c**, Western blot showing that treatment with SB203580 (to block p38 phosphorylation) prevents the nucleo-cytoplasmic translocation of HuR after 4 h culture onto laminin (**b**) and reduces the migration rate on laminin (**c**). **a**, **b**,  $\beta$ -Actin, Loading control. **a**, Gapdh, Cytoplasmic marker; Histone H3, nuclear marker. Cyto, Cytoplasmic fractions; Nucl, nuclear fractions.


8a) and showed that HuR specifically bound to its 3'-UTR by biotin pull-down assays (Fig. 8b). By RIP-qPCR, we also validated the binding of HuR to other myelination-related mRNAs (i.e., *Egr2*, *Prx*, *Mbp*, *Mpz*) with significantly decreased binding affinity in P5 nerves (Fig. 8c). This was a surprising observation since this pattern is inversely correlated to their total mRNA levels, which increase postnatally reaching a peak at approximately P10 (Verheijen et al., 2003).

To further examine the role of HuR in the process of myelination, we silenced *HuR* in cultured Schwann cells and examined expression of some of these myelination-related proteins by Western blotting. *HuR* silencing induced a significant increase in their levels, both under myelinogenic conditions and strikingly under basal conditions as well (Fig. 8d). By qPCR analysis, we also found increased levels of myelination-related mRNAs after *HuR* silencing both under basal (Fig. 8e) and myelinogenic conditions (Fig. 8f), which was opposite to its effects seen above for morphogenesis-, proliferation-, and apoptotic-related genes. Exposure to actinomycin D in cAMP-treated cells showed that the half-life of each mRNA was significantly longer in *HuR*-silenced cells than control cells (Fig. 8g), suggesting that HuR could be destabilizing these mRNAs, instead of its typical role as a stabilizing factor for target mRNAs.

These data indicate that HuR could be a negative regulator of myelination (Jessen and Mirsky, 2008). To show this, we examined myelination in dorsal root ganglion (DRG) cocultures, seeded with Schwann cells with altered levels of HuR. We found that *HuR* silencing significantly increased the number of MBP<sup>+</sup> segments in the cocultures ( $16.5 \pm 2.1\%$  in *HuR*-silenced cells compared with  $8.1 \pm 1.6\%$  in control cells;  $p < 0.01$ ) (Fig. 9a), accompanied by a significant increase in transcript expression (Fig. 9b). Conversely, enforced expression of HuR by adenoviral vectors decreased the number of MBP<sup>+</sup> segments ( $5.9 \pm 0.6\%$  in control cells compared with  $4.3 \pm 0.4\%$  in *HuR*-overexpressing cells;  $p < 0.05$ ) (Fig. 9c), accompanied by a small but significant decrease in the expression of some of these transcripts (Fig. 9d).

The above data argue for a potential role of HuR in inhibiting myelination, similar to Notch and c-Jun (Parkinson et al., 2008; Woodhoo et al., 2009).





**Figure 5.** HuR mediates NRG1- and TGF $\beta$ -induced proliferation. **a, b**, HuR silencing significantly reduces NRG1- (**a**) and TGF $\beta$ -induced (**b**) proliferation compared with sh control-infected cells as determined by BrdU incorporation (BrdU<sup>+</sup> cells, red; DAPI<sup>+</sup> nuclei, blue). **c**, qPCR showing expression of different transcripts after NRG1 or TGF $\beta$  treatment with time, expressed as fold change relative to untreated cells. **d**, RIP-qPCR analysis shows significant enrichment of proliferation-associated genes bound to HuR in NRG1- and TGF $\beta$ -treated cells compared with cells cultured in MM. **e, f**, HuR silencing leads to a significant reduction in expression of proliferation-associated genes after NRG1 (**e**) and TGF $\beta$  (**f**) treatment. Data are mean  $\pm$  SEM. \* $p$  < 0.01.

### HuR transcription is regulated by p65 and Smad2/3

HuR abundance plays a critical role in its function (Hinman and Lou, 2008). We showed that HuR mRNA levels decrease with development (Fig. 1a), and we wanted to examine the mechanisms that control this.

It has previously been shown in other systems that HuR transcription is positively regulated by the transcription factors (TFs) NF- $\kappa$ B (Kang et al., 2008) and Smads (Jeyaraj et al., 2010). We tested the recruitment of NF- $\kappa$ B to the HuR promoter in chromatin extracts from NB, P5, and P10 nerves by chromatin immunoprecipitation (ChIP) using antibodies against the p65 subunit

of NF- $\kappa$ B followed by qRT-PCR. We found significant binding of p65 to different putative consensus sites, with reduced affinity in P10 nerves compared with NB or P5 nerves (Fig. 10a). ChIP of Smad2/3 showed similar results (Fig. 10b), whereas no recruitment was seen with ChIP of Smad4 (data not shown). The decreased binding of p65 or Smad2/3 to the HuR promoter in P10 nerves is likely due to reduced nuclear expression of these TFs in these nerves (Fig. 10c).

Next, we examined the signaling pathways that could potentially regulate this mechanism. It was previously shown that NRG1 is sufficient to activate NF- $\kappa$ B in Schwann cells (Limpert

and Carter, 2010). We thus tested whether NRG1 was responsible for p65-mediated *HuR* transcription. We found that NRG1 treatment induced a transient increase in *HuR* mRNA and protein levels (Fig. 10*d*) and ChIP experiments showed that p65 was recruited to the *HuR* promoter after treatment with NRG1 for 1 h, but not for 12 h (Fig. 10*e*), following the kinetics of NRG1-induced *HuR* transcription (Fig. 10*d*). NRG1-induced increase in *HuR* levels was significantly attenuated by treatment with the NF- $\kappa$ B-specific inhibitor BAY11-7082, which prevents nuclear localization of p65 (Fig. 10*f*), confirming the role of NF- $\kappa$ B in NRG1-induced *HuR* transcription.

Similarly, we found that TGF $\beta$ , which induces nuclear translocation of Smad2/3 in Schwann cells (D'Antonio et al., 2006b), increased *HuR* mRNA and protein levels (Fig. 10*g*) and ChIP of Smad2/3 showed its recruitment to the *HuR* promoter after treatment for 1 h, but not 12 h later (Fig. 10*h*), following the kinetics of NRG1-induced *HuR* transcription (Fig. 10*g*). TGF $\beta$ -induced increase in *HuR* levels was significantly attenuated by enforced expression of Smad7 by adenoviral infection (Ad-Smad7), which prevents phosphorylation of Smad2/3 and its subsequent activation and translocation (Fig. 10*i*), confirming the role of Smad2/3 in TGF $\beta$ -induced *HuR* transcription. Combined treatment of NRG1 and TGF $\beta$  did not lead to an enhanced up-regulation of *HuR* levels seen by separate treatments of these growth factors at 2 h (Fig. 10*j*) and at 4 h (data not shown). Laminin treatment also had no effect on *HuR* transcription (data not shown).


Our data show that *HuR* transcription is dependent on the TFs NF- $\kappa$ B and Smad2/3 *in vivo*, likely to be regulated by NRG1 and TGF $\beta$ , respectively. Reduced expression of these TFs results in decreased *HuR* mRNA levels during development.

### Egr2 (Krox20) induces proteosomal degradation of HuR

Earlier, we found that *HuR* protein levels were significantly reduced in P10 nerves compared with NB or P5 nerves, whereas there was only a slight reduction in mRNA levels (Fig. 1*a–c*). Since we found previously that the TF Egr2, which plays a critical role in the myelination process (Topilko et al., 1994), can also suppress expression of several negative regulators of myelination, including Notch and c-Jun (Parkinson et al., 2008; Woodhoo et al., 2009), we examined whether it was responsible for this downregulation of *HuR* expression. We found that enforced Egr2 expression was sufficient to suppress *HuR* protein levels (Fig. 10*k*) without affecting mRNA levels (data not shown). This effect was dependent on the ubiquitin-proteosomal degradation pathway since treatment with the proteasome inhibitor MG132 diminished this effect (Fig. 10*l*).

## Discussion

Radial sorting plays a critical role in PNS myelination. We show that the RNA-binding protein *HuR* is highly expressed during this stage, where it is bound to and regulates expression of numerous genes regulating proliferation, apoptosis, and morpho-



**Figure 6.** NRG1 and TGF $\beta$  induce nucleo-cytoplasmic translocation of *HuR*. **a**, Western blot showing nucleo-cytoplasmic translocation of *HuR* after NRG1 and TGF $\beta$  treatment. **b**, Treatment with UO126 (to block ERK1/2 phosphorylation) or LY294002 (to block AKT phosphorylation) prevents NRG1-induced nucleo-cytoplasmic translocation of *HuR* (left panel) and proliferation (right panel). **c**, Treatment with UO126 or SB203580 prevents TGF $\beta$ -induced nucleo-cytoplasmic translocation of *HuR* (left panel) and proliferation (right panel). **a–c**,  $\beta$ -Actin, Loading control. **a**, Gapdh, Cytoplasmic marker; Histone H3, nuclear marker. Cyto, Cytoplasmic fractions; Nucl, nuclear fractions. Data are mean  $\pm$  SEM. \* $p < 0.01$ .


genesis. This supports the view that RBPs such as *HuR* perform their overall biological functions by coordinately regulating expression of multiple functionally related mRNAs, known as “RNA operons” (Keene, 2007). This association of *HuR* with mRNAs is dynamic, with a significant decrease in the population of target mRNAs in P5 nerves compared with NB nerves, coinciding with a general decrease in mRNA expression of some of them (Verheijen et al., 2003). This is in line with other studies, which show dynamic changes in the association of *HuR* with target mRNAs (Mazan-Mamczarz et al., 2008; Mukherjee et al., 2009), and supports the view that RNA accessibility partially determines the formation of RBP–mRNA complexes (Kazan et al., 2010).

### Schwann cell morphogenesis

Laminins play a major role in radial sorting with severe defects seen after *in vivo* ablation of laminin isoforms, receptors, and downstream signaling pathways (Chernousov et al., 2008; Feltri et al., 2008). Our data suggest that *HuR* could be an important mediator of laminin-induced function in Schwann cells by binding to and stabilizing laminin-induced mRNAs. *HuR* silencing *in vitro* results in decreased migration and significantly leads to morphological phenotypes, similar to cells lacking the laminin receptor  $\beta$ 1-integrin or its downstream effector Rac1 (Benninger et al., 2007; Nodari et al., 2007). This effect is likely controlled by p38-mediated nucleo-cytoplasmic translocation of *HuR*, which is an important determinant of its function (Doller et al., 2008).


### Schwann cell proliferation

Schwann cell proliferation is critical for matching axon and Schwann cell numbers during radial sorting, a process dependent on axonally derived mitogens (Chernousov et al., 2008; Feltri et al.,



**Figure 7.** HuR mediates TGF $\beta$ -induced apoptosis. **a, b**, HuR silencing leads to a significant reduction in TGF $\beta$  apoptosis as seen by number of surviving cells identified by nuclear condensation viewed by DAPI (blue) and number of apoptotic cells viewed by TUNEL labeling (green) (**a**), and Western blot of PARP cleavage and active caspase-3, 48 h after treatment (*Figure legend continues.*)





**Figure 8.** HuR is a negative regulator of myelination. **a**, RIP-qPCR analysis shows binding of HuR to *Pmp22* mRNA both in NB and P5 nerves. **b**, Schematic of *Pmp22* mRNA depicting the 5'-UTR, coding region, and 3'-UTR. *In silico* analysis revealed several computationally predicted HuR motifs (arrowheads), and biotinylated transcripts spanning different mRNA regions (A–E) were incubated with P5 sciatic nerve lysates and the interaction assessed by biotin pull-down assays followed by Western blot analysis. HuR only formed complexes with a specific region of the 3'-UTR, but not with the 5'-UTR or coding region. No interaction was seen with a control biotinylated RNA corresponding to the 3'-UTR of *GAPDH* mRNA, which is not a target of HuR (data not shown). **c**, RIP-qPCR analysis shows binding of HuR to several myelination-related genes in postnatal nerves. **d**, Western blot showing an increased expression of several myelination genes after *HuR* silencing under basal (MM) and myelinogenic conditions (dibutyl-cAMP treatment). **e**, **f**, qPCR showing an increased expression of myelination-related genes after *HuR* silencing in MM (**e**), and after cAMP treatment (**f**). **g**, qPCR showing the half-life of myelination-related genes in control and *HuR*-silenced cAMP-treated cells. Data are mean  $\pm$  SEM. \* $p < 0.01$ .

2008; Woodhoo and Sommer, 2008). NRG1 is likely to play a major role, as shown *in vitro* (Morrissey et al., 1995) and *in vivo* in zebrafish (Lyons et al., 2005; Raphael et al., 2011). Indirect evidence also exists in mice models *in vivo*, as shown in mutants lacking the downstream effector of NRG1 signaling *Cdc42* (Benninger et al., 2007) and in mice with neuronal overexpression of


NRG1 (Gomez-Sanchez et al., 2009). TGF $\beta$  is another important Schwann cell mitogen, both *in vitro* (Atanasoski et al., 2004) and *in vivo* (D'Antonio et al., 2006b). We show that NRG1 and TGF $\beta$  increase expression and binding of HuR to several proliferation-associated genes. *HuR* silencing decreases expression of these genes and consequently proliferation. Both signals induce nucleo-cytoplasmic translocation of HuR, an effect mediated by several kinases such as ERK1/2, which also regulate proliferation, in line with other studies for NRG1 (Maurel and Salzer, 2000; Echave et al., 2009) and TGF $\beta$  (Xie et al., 2007). This suggests that these kinases could regulate proliferation induced by these two growth factors, by increased nucleo-cytoplasmic translocation of HuR and stabilization of critical target genes.

### Schwann cell apoptosis

TGF $\beta$  is also a death signal for Schwann cells (D'Antonio et al., 2006b). We show that it increases expression and binding of HuR

(Figure legend continued.) **(b)**, **c**, qPCR showing expression of different transcripts after TGF $\beta$  treatment with time, expressed as fold change relative to untreated cells. **d**, RIP-qPCR analysis shows significant enrichment of apoptosis-associated genes bound to HuR in TGF $\beta$ -treated cells compared with cells cultured in SM. **e**, *HuR* silencing leads to a significant reduction in expression of these genes. **f**, Western blot showing nucleo-cytoplasmic translocation of HuR after TGF $\beta$  treatment. **g**, **h**, Treatment with SB203580, but not with U0126, prevents TGF $\beta$ -induced nucleo-cytoplasmic translocation of HuR (**g**) and apoptosis (**h**). **f**, **g**,  $\beta$ -Actin, loading control. **f**, **g**, Gapdh, cytoplasmic marker; Histone H3, nuclear marker. Cyto, cytoplasmic fractions; Nucl, nuclear fractions. Data are mean  $\pm$  SEM. \* $p < 0.01$ .





**Figure 9.** HuR regulates myelination in DRG cocultures. *a, b*, HuR silencing increases myelination in Schwann cell–DRG cocultures, as seen by number of MBP<sup>+</sup> myelin segments (red) (*a*), and qPCR analysis of myelination-related genes (*b*). *c, d*, Enforced HuR expression induced a small but significant decrease in myelination in Schwann cell–DRG cocultures, as seen by number of MBP<sup>+</sup> myelin segments (red) (*c*), and qPCR analysis of myelination-related genes (*d*). Gapdh, Loading control. Data are mean ± SEM. \**p* < 0.01.

to several apoptosis-associated genes. HuR silencing decreases expression of these genes and consequently apoptosis. This effect is likely mediated by an increased nucleo-cytoplasmic translocation of HuR, induced by TGFβ-mediated p38 phosphorylation, an important determinant of its function on apoptosis, as shown here and in other systems (Liao et al., 2001). It is quite striking that HuR mediates the effects of one single factor in two such distinct processes as proliferation and apoptosis. It has been proposed that TGFβ acts as a mitogen for cells in close contact with axons and an apoptotic signal for cells that have lost contact with axons (D'Antonio et al., 2006b). Such a context could explain the dual role of HuR; TGFβ, in concert with other mitogens such as NRG1 and laminins, would induce ERK1/2-mediated cytoplasmic localization of HuR and/or increase binding to and stability of proliferation-associated genes. Upon loss of axonal contact, TGFβ, alone or in concert with other death signals, would induce p38-mediated cytoplasmic localization of HuR and/or increase binding to and stability of apoptosis-associated genes.

### Negative regulator of myelination

Our RIP-chip analysis identified a number of myelination-related genes as HuR targets (e.g., *Egr2*, *Pmp22*, *Mpz*) in NB nerves, which was surprising since these genes are upregulated later in development. Further analysis suggests that HuR, in contrast to its typical function, decreases their stability and translation. This is in agreement with recent reports, which also show that HuR can destabilize target mRNAs such as *p16(INK4)* and *Daf* (Chang et al., 2010; Gray et al., 2010) and repress translation of genes such as *p27* (Hinman and Lou, 2008). This function of HuR is likely to prevent ectopic expression of myelin genes in immature Schwann cells before they segregate into 1:1 relationship with axons, such that myelin is not abnormally formed around axon–Schwann cell families. With subsequent development, as most of the promyelinating Schwann cells are formed, HuR no longer binds to and destabilizes these genes as shown by RIP-chip analysis of P5 nerves, allowing myelination to proceed normally.

The mechanisms that lead to this switch in binding affinity of HuR to these mRNAs at different stages of development could be regulated by different posttranslational modifications (Doller et al., 2008). Thus, in NB nerves, a specific posttranslational modification of HuR (e.g., phosphorylation) could make it amenable to binding to these mRNAs. After radial sorting, either loss of this modification and/or a different modification, in response to myelination signals, could prevent its binding to these mRNAs. In addition, HuR abundance, which also determines its function (Hinman and Lou, 2008), could be another important factor in regulating this switch. In P10 nerves, which correspond to stages of peak of myelination, HuR levels are considerably decreased. Thus, the low levels of HuR could also explain its decreased binding to the myelin protein-related mRNAs.


### Control of HuR expression

Finally, we show that the TFs NF-κB and Smad2/3 are bound to specific sites in the *HuR* promoter *in vivo*, as shown in other systems (Kang et al., 2008; Jeyaraj et al., 2010). The decreased expression of *HuR* mRNA levels in P10 nerves is likely due to a reduced activation of these TFs, as shown previously for NF-κB (Nickols et al., 2003), resulting in a decreased binding to the *HuR* promoter. We also identify NRG1 and TGFβ as the signals that respectively recruit NF-κB and Smad2/3 to the *HuR* promoter. This is likely to be important *in vivo* to maintain high levels of HuR in early postnatal nerves.

In addition, HuR has been found to autoregulate its levels by binding to *HuR* mRNA, stabilizing it (Al-Ahmadi et al., 2009), and enhancing its cytoplasmic export (Yi et al., 2010). In our RIP-chip assay, we found an enrichment of *HuR* mRNA in both NB and P5 nerves, showing that HuR is likely to be regulating its stability during Schwann cell development. We also found a significant reduction of HuR protein in P10 nerves, which is unlikely to be due to the small decrease in *HuR* mRNA levels. We show instead that this could depend on ubiquitin-proteasomal degradation, as described previously (Abdelmohsen et al., 2009), mediated by the transcription factor Egr2, which similarly represses expression of other negative regulators of myelination, including Notch (Woodhoo et al., 2009), and c-Jun and Sox2 (Parkinson et al., 2008). miRNAs could also potentially play a significant role in this process since *HuR* translation can be blocked by two different miRNAs, miR-519 (Abdelmohsen et al., 2008) and miR-125a (Guo et al., 2009), and miRNAs play a significant role in radial sorting, proliferation, and apoptosis during early postnatal Schwann cell development (Dugas and Notterpek, 2011).

### *In vivo* functions of HuR?

It would be important to examine HuR function *in vivo*. Since *HuR* knock-out mice are embryonically lethal (Katsanou et al., 2009), Schwann cell-specific ablation of HuR would need to be performed using established cre mouse lines (Woodhoo et al., 2009). These mice could be characterized by peripheral nerve



**Figure 10.** HuR expression is controlled by p65 and Smad2/3-induced transcription. **a, b**, Schematic diagram of the promoter region of *HuR* showing NF- $\kappa$ B consensus binding sites (green ovals) and regions analyzed (A1 and A2) (**a**) and SMAD2/3 consensus binding sites (yellow ovals) and regions analyzed (B1 and B2) (**b**). ChIP analysis shows a decreased binding of p65 and SMAD2/3 to the regions analyzed, in P10 nerves compared with NB and P5 nerves. **c**, Western blot showing reduced p65 and SMAD2/3 expression in nuclear fractions of P10 nerves compared with NB and P5 nerves. **d–f**, NRG1 increases *HuR* transcription through NF- $\kappa$ B activation. **d**, Treatment with NRG1 increases *HuR* mRNA (top panel) and *HuR* protein levels (bottom panel), as seen by qPCR and Western blotting, respectively. **e**, ChIP analysis shows that p65 is recruited to the *HuR* promoter regions (indicated in **a**) after treatment with NRG1 for 1 h, but not in cells cultured in MM, or with NRG1 for 12 h. **f**, Western blot showing that treatment with the NF- $\kappa$ B inhibitor BAY11-7082, which prevents the nuclear translocation of p65, inhibits the NRG1-induced increase in *HuR* levels. **g–i**, TGF $\beta$  increases *HuR* transcription through SMAD2/3 activation. **g**, Treatment with TGF $\beta$  increases *HuR* mRNA (top panel) and *HuR* protein levels (bottom panel), as seen by qPCR and Western blotting, respectively. **h**, ChIP analysis shows that SMAD2/3 is recruited to the *HuR* promoter regions (indicated in **b**) after treatment with TGF $\beta$  for 1 h, but not in cells cultured in MM, or with TGF $\beta$  for 12 h. **i**, Western blot showing that adenoviral infection of cells with SMAD7 adenovirus (Ad-SMAD7), which prevents the nuclear translocation of SMAD2/3, inhibits the TGF $\beta$ -induced increase in *HuR* levels. **j**, Combined treatment of NRG1 and TGF $\beta$  of Schwann cells plated onto laminin did not lead to an enhanced upregulation of *HuR*, induced by the two growth factors alone, as seen by qPCR (top panel) and Western blot (bottom panel), 2 h after treatment. **k, l**, Western blots showing that adenoviral infection of cells with Egr2 adenovirus (Ad-Egr2) decreases *HuR* levels after 48 h (**k**), an effect reduced with treatment with the proteasome inhibitor MG132 (**l**).  $\beta$ -Actin/Gapdh, Loading control. Nuc, Nuclear fractions. Data are mean  $\pm$  SEM. \* $p < 0.01$ .

defects, including impairment in radial sorting and/or premature myelination, given the range of features, such as laminin-induced morphological functions that HuR controls in immature Schwann cells *in vitro*. This would be similar to mice lacking different laminin isoforms, laminin receptors, and downstream targets such as Rac1 (Chernousov et al., 2008; Feltri et al., 2008). These pleiotropic functions of HuR and the range of mRNAs it interacts with, also raise the possibility that it could have impor-

tant functions in adult nerves, controlling features such as de-differentiation. Following nerve injury, for example, Schwann cells de-differentiate to a phenotype closely resembling immature Schwann cells (Jessen and Mirsky, 2008). They downregulate myelination genes, break down their myelin, and proliferate rapidly, and some of the supernumerary ones undergo apoptosis (Yang et al., 2008). HuR could be mediating injury-induced responses of Schwann cells, including proliferation and apoptosis, as some of

the identified HuR targets in Schwann cells such as *Cyclin D1* are reexpressed upon injury and have important physiological functions during the de-differentiation process (Kim et al., 2000; Atanasoski et al., 2001).

## Notes

Supplemental material for this article is available at <http://www.ebi.ac.uk/arrayexpress/experiments/E-MEXP-3519>. Raw and processed microarray data are publicly accessible at EMBO-EBI ArrayExpress database under accession number E-MEXP-3519. This material has not been peer reviewed.

## References

- Abdelmohsen K, Srikantan S, Kuwano Y, Gorospe M (2008) miR-519 reduces cell proliferation by lowering RNA-binding protein HuR levels. *Proc Natl Acad Sci U S A* 105:20297–20302.
- Abdelmohsen K, Srikantan S, Yang X, Lal A, Kim HH, Kuwano Y, Galban S, Becker KG, Kamara D, de Cabo R, Gorospe M (2009) Ubiquitin-mediated proteolysis of HuR by heat shock. *EMBO J* 28:1271–1282.
- Al-Ahmadi W, Al-Ghamdi M, Al-Hajj L, Al-Saif M, Khabar KS (2009) Alternative polyadenylation variants of the RNA binding protein, HuR: abundance, role of AU-rich elements and auto-regulation. *Nucleic Acids Res* 37:3612–3624.
- Antic D, Keene JD (1997) Embryonic lethal abnormal visual RNA-binding proteins involved in growth, differentiation, and posttranscriptional gene expression. *Am J Hum Genet* 61:273–278.
- Atanasoski S, Shumas S, Dickson C, Scherer SS, Suter U (2001) Differential cyclin D1 requirements of proliferating Schwann cells during development and after injury. *Mol Cell Neurosci* 18:581–592.
- Atanasoski S, Notterpek L, Lee HY, Castagner F, Young P, Ehrenguber MU, Meijer D, Sommer L, Stavnezer E, Colmenares C, Suter U (2004) The protooncogene *Ski* controls Schwann cell proliferation and myelination. *Neuron* 43:499–511.
- Benninger Y, Thurnherr T, Pereira JA, Krause S, Wu X, Chrostek-Grashoff A, Herzog D, Nave KA, Franklin RJ, Meijer D, Brakebusch C, Suter U, Relvas JB (2007) Essential and distinct roles for *cdc42* and *rac1* in the regulation of Schwann cell biology during peripheral nervous system development. *J Cell Biol* 177:1051–1061.
- Berti C, Bartesaghi L, Ghidinelli M, Zambroni D, Figlia G, Chen ZL, Quattrini A, Wrabetz L, Feltri ML (2011) Non-redundant function of dystroglycan and beta1 integrins in radial sorting of axons. *Development* 138:4025–4037.
- Blaney Davidson EN, Vitters EL, van den Berg WB, van der Kraan PM (2006) TGF beta-induced cartilage repair is maintained but fibrosis is blocked in the presence of Smad7. *Arthritis Res Ther* 8:R65.
- Chang N, Yi J, Guo G, Liu X, Shang Y, Tong T, Cui Q, Zhan M, Gorospe M, Wang W (2010) HuR uses AUF1 as a cofactor to promote p16INK4 mRNA decay. *Mol Cell Biol* 30:3875–3886.
- Chen Y, Wang H, Yoon SO, Xu X, Hottiger MO, Svaren J, Nave KA, Kim HA, Olson EN, Lu QR (2011) HDAC-mediated deacetylation of NF-kappaB is critical for Schwann cell myelination. *Nat Neurosci* 14:437–441.
- Chen ZL, Strickland S (2003) Laminin gamma1 is critical for Schwann cell differentiation, axon myelination, and regeneration in the peripheral nerve. *J Cell Biol* 163:889–899.
- Chernousov MA, Yu WM, Chen ZL, Carey DJ, Strickland S (2008) Regulation of Schwann cell function by the extracellular matrix. *Glia* 56:1498–1507.
- D'Antonio M, Michalovich D, Paterson M, Droggiti A, Woodhoo A, Mirsky R, Jessen KR (2006a) Gene profiling and bioinformatic analysis of Schwann cell embryonic development and myelination. *Glia* 53:501–515.
- D'Antonio M, Droggiti A, Feltri ML, Roes J, Wrabetz L, Mirsky R, Jessen KR (2006b) TGFβ type II receptor signaling controls Schwann cell death and proliferation in developing nerves. *J Neurosci* 26:8417–8427.
- Doller A, Pfeilschifter J, Eberhardt W (2008) Signalling pathways regulating nucleo-cytoplasmic shuttling of the mRNA-binding protein HuR. *Cell Signal* 20:2165–2173.
- Du P, Kibbe WA, Lin SM (2008) lumi: a pipeline for processing Illumina microarray. *Bioinformatics* 24:1547–1548.
- Dugas JC, Notterpek L (2011) MicroRNAs in oligodendrocyte and Schwann cell differentiation. *Dev Neurosci* 33:14–20.
- Echave P, Machado-da-Silva G, Arkell RS, Duchon MR, Jacobson J, Mitter R, Lloyd AC (2009) Extracellular growth factors and mitogens cooperate to drive mitochondrial biogenesis. *J Cell Sci* 122:4516–4525.
- Feltri ML, Suter U, Relvas JB (2008) The function of RhoGTPases in axon ensheathment and myelination. *Glia* 56:1508–1517.
- Fragoso G, Robertson J, Athlan E, Tam E, Almazan G, Mushynski WE (2003) Inhibition of p38 mitogen-activated protein kinase interferes with cell shape changes and gene expression associated with Schwann cell myelination. *Exp Neurol* 183:34–46.
- Gomez-Sanchez JA, Lopez de Armentia M, Lujan R, Kessaris N, Richardson WD, Cabello H (2009) Sustained axon-glia signaling induces Schwann cell hyperproliferation, Remak bundle myelination, and tumorigenesis. *J Neurosci* 29:11304–11315.
- Gray LC, Hughes TR, van den Berg CW (2010) Binding of human antigen R (HuR) to an AU-rich element (ARE) in the 3'-untranslated region (3'-UTR) reduces the expression of decay accelerating factor (DAF). *Mol Immunol* 47:2545–2551.
- Guo X, Wu Y, Hartley RS (2009) MicroRNA-125a represses cell growth by targeting HuR in breast cancer. *RNA Biol* 6:575–583.
- Hieronymus H, Silver PA (2003) Genome-wide analysis of RNA-protein interactions illustrates specificity of the mRNA export machinery. *Nat Genet* 33:155–161.
- Hinman MN, Lou H (2008) Diverse molecular functions of Hu proteins. *Cell Mol Life Sci* 65:3168–3181.
- Houzelstein D, Bullock SL, Lynch DE, Grigorieva EF, Wilson VA, Beddington RS (2002) Growth and early postimplantation defects in mice deficient for the bromodomain-containing protein Brd4. *Mol Cell Biol* 22:3794–3802.
- Jacob C, Christen CN, Pereira JA, Somandini C, Baggolini A, Lötscher P, Özçelik M, Tricaud N, Meijer D, Yamaguchi T, Matthias P, Suter U (2011) HDAC1 and HDAC2 control the transcriptional program of myelination and the survival of Schwann cells. *Nat Neurosci* 14:429–436.
- Jena N, Deng M, Sicinska E, Sicinski P, Daley GQ (2002) Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. *Cancer Res* 62:535–541.
- Jessen KR, Mirsky R (2005) The origin and development of glial cells in peripheral nerves. *Nat Rev Neurosci* 6:671–682.
- Jessen KR, Mirsky R (2008) Negative regulation of myelination: relevance for development, injury, and demyelinating disease. *Glia* 56:1552–1565.
- Jeyaraj SC, Singh M, Ayupova DA, Govindaraju S, Lee BS (2010) Transcriptional control of human antigen R by bone morphogenetic protein. *J Biol Chem* 285:4432–4440.
- Kang MJ, Ryu BK, Lee MG, Han J, Lee JH, Ha TK, Byun DS, Chae KS, Lee BH, Chun HS, Lee KY, Kim HJ, Chi SG (2008) NF-kappaB activates transcription of the RNA-binding factor HuR, via PI3K-AKT signaling, to promote gastric tumorigenesis. *Gastroenterology* 135:2030–2042, 2042.e1–e3.
- Katsanov V, Milatos S, Yiakoukaki A, Sgantzis N, Kotsoni A, Alexiou M, Harokopos V, Aidinis V, Hemberger M, Kontoyiannis DL (2009) The RNA-binding protein Elavl1/HuR is essential for placental branching morphogenesis and embryonic development. *Mol Cell Biol* 29:2762–2776.
- Kazan H, Ray D, Chan ET, Hughes TR, Morris Q (2010) RNAcontext: a new method for learning the sequence and structure binding preferences of RNA-binding proteins. *PLoS Comput Biol* 6:e1000832.
- Keene JD (2007) RNA regulons: coordination of post-transcriptional events. *Nat Rev Genet* 8:533–543.
- Keene JD, Komisarow JM, Friedersdorf MB (2006) RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts. *Nat Protoc* 1:302–307.
- Kim HA, Pomeroy SL, Whoriskey W, Pawlitzky I, Benowitz LI, Sicinski P, Stiles CD, Roberts TM (2000) A developmentally regulated switch directs regenerative growth of Schwann cells through cyclin D1. *Neuron* 26:405–416.
- Kumar S (2009) Caspase 2 in apoptosis, the DNA damage response and tumour suppression: enigma no more? *Nat Rev Cancer* 9:897–903.
- Lankat-Buttgereit B, Göke R (2009) The tumour suppressor Pcd4: recent advances in the elucidation of function and regulation. *Biol Cell* 101:309–317.
- Larsson C (2006) Protein kinase C and the regulation of the actin cytoskeleton. *Cell Signal* 18:276–284.
- Lebedeva S, Jens M, Theil K, Schwanhäusser B, Selbach M, Landthaler M, Rajewsky N (2011) Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. *Mol Cell* 43:340–352.
- Lee H, Cha S, Lee MS, Cho GJ, Choi WS, Suk K (2003) Role of antiproliferative B cell translocation gene-1 as an apoptotic sensitizer in activation-induced cell death of brain microglia. *J Immunol* 171:5802–5811.



